The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Accelerating Biological Understanding and Therapeutic Translation for PD-Biology, 2024Study of Multiple Air Pollutants in Parkinson’s Disease (MAP-PD)
Study Rationale: Chemicals in our environment, including some air pollutants, likely contribute to the development of Parkinson’s disease (PD). However, relatively few chemicals have been identified...
-
Accelerating Biological Understanding and Therapeutic Translation For Parkinson’s Disease- Biology, 2024Establishing a Cohort of Carriers with ATP13A2 Mutations for Clinical and Biomarker Analysis
Study Rationale: Polyamines are molecules that show neuroprotective effects, and one of the genes that is mutated in Parkinson’s disease (PD), ATP13A2, regulates cellular polyamine levels. Unpublished...
-
Accelerating Biological Understanding and Therapeutic Translation for PD-Biology, 2024Investigating the Effects of Pesticide Exposure on Immune System Function in Parkinson’s Disease
Study Rationale: Although it is well known that exposure to environmental substances, including pesticides, contributes considerably to Parkinson’s disease (PD), the mechanisms are largely unexplored...
-
ASAP CRN Competitive Renewal Opportunity, 2024Studying the Pathogenesis of Parkinson’s Disease Via Single-cell Analysis of Human Brain and Gut Cells: A Basis for Clinical Translation
Study Rationale: More than 100 regions of the chromosomes that we inherit from our parents show differences in DNA sequence between people with and without Parkinson’s disease (PD). Furthermore, as we...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2024Phase 2a Clinical Study of HBI-002 in Parkinson’s Disease
Study Rationale: A growing body of research suggests that low doses of carbon monoxide (CO) protect against neuronal cell loss in Parkinson’s disease (PD). Preclinical efficacy data in two rodent...
-
ASAP CRN Competitive Renewal Opportunity, 2024Identifying Mechanisms that Overwhelm Protein and Organelle Quality Control in Parkinson’s Disease
Study Rationale: Abnormal protein aggregation and prion-like aggregate spreading are hallmarks of the degenerative cascades of sporadic and familial Parkinson’s disease (PD). These toxic aggregates...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.